Gilead Sciences (GILD) : $106.33 million worth of transactions were on upticks in Gilead Sciences (GILD), compared to $95.51 million on downticks. The ratio between the two was 1.11, whereas, the net money flow stood at a healthy $10.82 million on Thursdays session.The block trades show a bullish bias with only $4.89 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $9.99million worth of trades. The up-down ratio between the uptick and downtick was 2.04, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $5.1 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.3%. The stock was trading at $85.47, with a drop of $0.26 over the previous days close. The stock recorded 0.72% for the week.
Gilead Sciences (GILD) : The consensus price target for Gilead Sciences (GILD) is $115.71 for the short term with a standard deviation of $11.72. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $135, however, the pessimist price target for the company is $96. The stock has recorded a 20-day Moving Average of 2.71% and the 50-Day Moving Average is 0.47%.
Gilead Sciences (NASDAQ:GILD): The stock opened at $85.90 on Thursday but the bulls could not build on the opening and the stock topped out at $86.26 for the day. The stock traded down to $84.77 during the day, due to lack of any buying support eventually closed down at $85.47 with a loss of -0.30% for the day. The stock had closed at $85.73 on the previous day. The total traded volume was 6,764,476 shares.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.